medigraphic.com

2007, Number 3

<< Back Next >>

Rev Educ Bioquimica 2007; 26 (3)

Expresión de ácido siálico y de la β-Galactósido-α-2, 6-Sialiltransferasa en cáncer

López MD, Vallejo V

Language: Spanish
References: 24
Page: 93-98
PDF size: 47.25 Kb.


ABSTRACT

Modifications of cellular sialylation are common phenotypical changes in malignancy. These changes in sialylation are related to grade, invasion and metastasis with a poor prognosis. The increase of α-2,6-sialylation of cell surface glycoconjugates of carcinoma cells has been reported. The molecular basis of the increase of α-2,6-sialic acid is related to the alterations in the sialyltransferasa ST6Gal I expression, enzyme that mediates α-2,6-sialylation of type 2 chains on glycoproteins. ST6Gal I regulation is achieved at transcriptional level. The interest of this paper is to analyze the available information concerning the ST6Gal I over-expression in cancer and the functional consequences of an increased sialylation of cell surface glycoconjugates of carcinoma cells.


REFERENCES

  1. Travig C, Schauer R (1998) Structure, function and metabolism of sialic acids. Cell Mol Life Sci 54:1330-1349.

  2. Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P (2001) The human sialyltransferases family. Biochemie 83:727-737.

  3. Haltiwanger RS (2002) Regulation of signal transduction pathways in development by glycosylation. Curr Op Struct Biol 12:593-598.

  4. Lowe JB (1999) Structures common to different types of glycans. En: Essentials of glycobiology, Chapter 16. Col Spring Harbor Laboratory Press. New York. 211-252.

  5. Travig C, Schauer R (1998) Structure, function and metabolism of sialic acids. Cell Mol Life Sci 54:1330-1349.

  6. Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P (2001) The human sialyltransferases family. Biochemie 83:727-737.

  7. Haltiwanger RS (2002) Regulation of signal transduction pathways in development by glycosylation. Curr Op Struct Biol 12:593-598.

  8. Lowe JB (1999) Structures common to different types of glycans. En: Essentials of glycobiology, Chapter 16. Col Spring Harbor Laboratory Press. New York. 211-252.

  9. Dall'Olio F, Chiricolo M (2001) Sialyltransferases in cancer. Glycoconj J 18:841-850.

  10. Dall'Olio F (2000) The sialyl-alpha2,6-lactosaminylstructure: biosynthesis and functional role. Glycoconj J 17:669-676.

  11. Kannagi R (2002) Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. Curr Op Struct Biol 12:599-608.

  12. Leffler H (2001) Galectins structure and function. Results Probl Cell Differ 33:57-83.

  13. Hennet T, Chui D, Paulson JC, Marth JD (1998) Immune regulation by the ST6Gal sialyltransferase. Proc Natl Acad Sci 95:4504-4509.

  14. Dall'Olio F, Malagolini N, Di Stefano G, Minni F, Marrano D, Serafini Cessi F (1989) Increased CMPNeuAc: Gal 1,4 GlcNac-R 2,6-sialyltransferase activity in human colorectal cancer tissues. Int J Cancer 44:434-439.

  15. Gessner P, Riedl S, Quentmaier A, Kemmner W (1993) Enhanced activity of CMP-NeuAc:Gal beta 1-4GlcNAc:alpha 2,6-sialyltransferase in metastasizing human colorectal tumor tissue and serum of tumor patients. Cancer Lett 75:143-149.

  16. Dall'Olio F, Chiricolo M, D'Errico A, Gruppioni E, Altimari A, Fiorentino M, Grigioni WF (2004) Expression of beta-galactoside alpha2,6 sialyltransferase and of alpha2,6-sialylated glycoconjugates in normal human liver, hepatocarcinoma, and cirrhosis. Glycobiology 14:39-49.

  17. Recchi MA, Hebbar M, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P (1998) Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Cancer Res 58:4066-4070.

  18. Wang PH, Lee WL, Lee YR, Juang CM, Chen YJ, Chao HT, Tsai YC, Yuan CC (2003) Enhanced expression of alpha 2,6-sialyltransferase ST6Gal I in cervical squamous cell carcinoma. Gynecol Oncol 89:395-401.

  19. Lin S, Kemmner W, Grigull S, Schlag PM (2002) Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells. Exp Cell Res 276:101-110.

  20. Chiricolo M, Malagolini N, Bonfiglioli S, Dall'Olio F (2006) Phenotypic changes induced by expression of beta-galactoside alpha-2,6-sialyltransferase I in the human colon cancer cell line SW948. Glycobiology 16:146-54.

  21. Wen DX, Svensson EC, Paulson JC (1992) Tissue-specific alternative splicing of the beta-galactoside alpha 2,6-sialyltransferase J Biol Chem 267:2512-2518.

  22. Lo NW, Lau JT (1996) Transcription of the beta-galactoside alpha 2,6-sialyltransferase gene in B lymphocytes is directed by a separate and distinct promoter. Glycobiology 6:271-279.

  23. Aas-Eng DA, Asheim HC, Deggerdal A, Smeland E, Funderud S (1995) Characterization of a promoter region supporting transcription of a novel human betagalactoside alpha-2,6-sialyltransferase transcript in HepG2 cells. Biochim Biophys Acta 1261:166-9.

  24. Xu L, Kurusu Y, Takizawa K, Tanaka J, Matsumoto K, Taniguchi A (2003) Transcriptional regulation of human beta-galactoside alpha2,6-sialyltransferase (hST6Gal I) gene in colon adenocarcinoma cell line. Biochem Biophys Res Commun 307:1070-1074.




2020     |     www.medigraphic.com